Coronary vasomotion abnormalities play important roles in the pathogenesis of ischaemic heart disease, in which endothelial dysfunction and coronary artery spasm are substantially involved. Endothelial vasodilator functions are heterogeneous depending on the vessel size, with relatively greater role of nitric oxide (NO) in conduit arteries and predominant role of endothelium-derived hyperpolarizing factor (EDHF) in resistance arteries, where endothelium-derived hydrogen peroxide serves as an important EDHF. The functions of NO synthases in the endothelium are also heterogeneous with multiple mechanisms involved, accounting for the diverse functions of the endothelium in vasomotor as well as metabolic modulations. Cardiovascular abnormalities and metabolic phenotypes become evident when all three NO synthases are deleted, suggesting the importance of both NO and EDHF. Coronary artery spasm plays important roles in the pathogenesis of a wide range of ischaemic heart disease. The central mechanism of the spasm is hypercontraction of vascular smooth muscle cells (VSMCs), but not endothelial dysfunction, where activation of Rho-kinase, a molecular switch of VSMC contraction, plays a major role through inhibition of myosin light-chain phosphatase. The Rho-kinase pathway is also involved in the pathogenesis of a wide range of cardiovascular diseases and new Rho-kinase inhibitors are under development for various indications. The registry study by the Japanese Coronary Spasm Association has demonstrated many important aspects of vasospastic angina. The ongoing international registry study of vasospastic angina in six nations should elucidate the unknown aspects of the disorder. Coronary vasomotion abnormalities appear to be an important therapeutic target in cardiovascular medicine.
Introduction
Coronary vasomotion is an important determinant of coronary vascular resistance and thus coronary blood flow, which is regulated by multiple mechanisms, including the endothelium, vascular smooth muscle cells (VSMCs), myocardial metabolic demand, autonomic nervous system, and inflammation. 1 -8 In the current era of coronary intervention, much attention has been paid to structural abnormalities of the coronary artery and less attention to its functional abnormalities. However, 10% of all patients with and up to 30% of female patients with acute coronary syndrome 9 and more than 60% of patients with chest pain undergoing elective coronary angiography 10 have no evidence of organic coronary artery stenosis, indicating the involvement of functional coronary vasomotion abnormalities. Indeed, the coronary artery (and other arteries as well) should be regarded as functional conduit rather than structurally rigid pipes. This review article will briefly summarize the 2014 William Harvey Lecture by the author. In this article, the translational research on coronary vasomotion abnormalities in the author's laboratory will be briefly reviewed, with a special reference to endothelial modulation of vascular tone and coronary artery spasm.
Endothelial modulation of vascular tone
The endothelium plays an important role in the modulation of vascular tone by synthesizing and releasing several vasodilator substances, collectively named as endothelium-derived relaxing factors (EDRFs), including vasodilator prostaglandins [mainly prostaglandin I 2 (PGI 2 )], nitric oxide (NO), and endothelium-derived hyperpolarizing factor (EDHF; Figure 1A ). 11 -16 The term EDRF(s) is currently used in two †
The 2014 William Harvey Lecture was given by the author on 31 August 2014, during the ESC Congress, Barcelona, Spain. different ways; one is strictly related to NO based on the original report 11 and the another is related to all vasodilating substances released from the endothelium. 12, 13 In this article, the author takes the latter position.
Relative importance of endothelium-derived relaxing factors as a function of vessel size Endothelium-derived NO mediates vascular relaxation of relatively large, conduit arteries (i.e. aorta and epicardial coronary arteries), while EDHF plays an important role in modulating vascular tone of resistance arteries (e.g. coronary microvessels) ( Figure 1A ).
17,18
Endothelium-derived hyperpolarizing factor causes vascular relaxation by opening calcium-activated K (K Ca ) channels and then hyperpolarizes membrane of VSMC ( Figure 1B) . 12, 13, 19 Endothelium-derived hyperpolarizing factor is synthesized not only upon stimulation by agonists but also by shear stress as in the case of NO. 20 Nature of endothelium-derived hyperpolarizing factor(s) Although the nature of EDHF has not been fully elucidated, different EDHFs could exist depending on species, blood vessels, and the size of blood vessels tested. 12, 21 Since the first report on the existence of Figure 1B) . 27 Based on the similarities between NO and EDHF in terms of susceptibility to atherosclerotic risk factors and responses to medications, we postulated that endothelial NO synthase (eNOS) might be a source of not only NO but also EDHF. 28 Using eNOS-deficient (eNOS 2/2 ) mice, we were able to identify that endothelium (eNOS)-derived hydrogen peroxide (H 2 O 2 ) is an EDHF in mouse mesenteric arteries. 28 We then confirmed that this is also the case in human mesenteric arteries 29 and porcine 30 and canine 31 coronary microvessels ( Figure 1B ). Other investigators also reported that endothelium-derived H 2 O 2 is an EDHF in piglet pial arterioles 32 and human coronary microvessels. 33 We further (Figure 2A) , the EDHF responses of mesenteric arteries were progressively reduced as the number of deleted NOS gene increased and were finally abolished in triply NOSs 2/2 mice ( Figure 2B) , whereas vasodilator and hyperpolarizing responses of VSMC per se were preserved. 37 These results provided us with the novel concept that endothelial NOSs system plays an important role as the EDHF-generating system in microvessels, while the system acts as the NO-generating system in large conduit arteries in its original meaning ( Figure 2C ). 37 In contrast, the contribution of other oxygenases to EDHF responses may be minimal as pharmacological or genetic blockade of those oxygenases had no effects on the responses ( Figures 1B and 2C ).
38
Vasodilating mechanisms of hydrogen peroxide/ endothelium-derived hyperpolarizing factor Hydrogen peroxide has been reported to cause vasodilatation through several mechanisms, including cGMP, cAMP, cyclooxygenase, and several K channels, depending on blood vessels tested. 21 Importantly, as an EDHF in microcirculation, H 2 O 2 rapidly reaches VSMC, stimulates the 1a isoform of cGMP-dependent protein kinase (PKG1a) to form disulfide form and opens K Ca channels with subsequent VSMC hyperpolarization and relaxation ( Figure 3) . 39 Hydrogen peroxide/EDHF plays an important role in blood pressure regulation as mice with dysfunctional PKG1a exhibit hypertension.
39
Mechanisms for enhanced endothelium-derived hyperpolarizing factor responses in microvessels Endothelium-derived hyperpolarizing factor responses appear to be the back-up system for NO responses that are easily impaired by atherosclerotic risk factors. 21 Thus, we aimed to elucidate the molecular mechanisms for enhanced EDHF responses in microvessels in mice in order to seek for a new strategy for atherosclerosis. The results showed that when compared with the aorta, eNOS is functionally suppressed in microvessels, for which Ca 2+ /calmodulindependent protein kinase kinase b (CaMKKb) and caveolin-1 are involved and that relaxation responses of VSMC to H 2 O 2 are enhanced through PKG1a-mediated mechanism ( Figure 3) . 40 Thus, multiple mechanisms are involved in the enhanced EDHF responses in microvessels ( Figure 3) . 21, 40 We have recently demonstrated the important role of the bone marrow (BM) in modulating microvascular endothelial and metabolic functions. 41 In this study, reduced microvascular endothelial and metabolic functions in eNOS
mice were improved by transplantation of wild-type BM but not eNOS 2/2 -BM and that those improvements were absent in doubly eNOS 2/2 /adiponectin 2/2 or e/nNOS 2/2 mice. 41 Thus, the BM plays an important role in modulating microvascular endothelial and metabolic functions, for which adiponectin and nNOS may be involved. 41 Recently, we have also demonstrated that endothelial AMP-activated protein kinase (AMPK), an important metabolic regulator, plays a crucial role in EDHF responses in microvessels (but not in the aorta), regulating blood pressure and coronary flow responses in mice in vivo ( Figure 3 ).
42
Clinical importance of hydrogen peroxide/ endothelium-derived hyperpolarizing factor Since EDHF responses are defined as the remaining responses after the blockade of those mediated by vasodilator PGs and NO, it is not so easy to precisely evaluate the in vivo importance of EDHF, especially in humans. However, the existence of EDHF-mediated responses has been repeatedly documented in isolated human arteries 29, 33 and human forearm circulation in vivo. 43 -47 In the canine coronary microcirculation in vivo, endothelium-derived H 2 O 2 exerts important cardioprotective effects, including coronary autoregulation, 31 myocardial protection against ischaemia/reperfusion injury, 48 and metabolic coronary dilatation ( Figure 3) . 49 Furthermore, EDHF responses are abolished when all three NOS isoforms are absent in the triply NOS 2/2 mice. 21, 37 Importantly, those mice exhibit typical characteristics of metabolic syndrome in humans, including visceral obesity, hypertension, glucose intolerance, and dyslipidaemia with a reduced survival (mainly due to myocardial infarction), indicating the important roles of the NOSs system to maintain cardiovascular and metabolic homeostasis ( Figure 4A and B). 36, 50, 51 It has been reported that EDHF responses are impaired in postmenopausal women 43 and patients with coronary artery disease 44 and are improved by short-term oestrogen-replacement therapy and longterm oral treatment with eicosapentaenoic acid, respectively.
Coronary artery spasm
Coronary artery spasm plays an important role in a wide variety of ischaemic heart diseases not only in variant angina but also in unstable angina, myocardial infarction, and sudden death. 52 -54 Since coronary artery spasm can be induced by a variety of stimuli with different mechanisms of action (even in the same patient), the occurrence of the spasm appears to be due to local hyperreactivity of the coronary artery rather than to an enhanced stimulation with a single mechanism of action. 55, 56 To elucidate the cellular and molecular Translational research on coronary vasomotion mechanisms of the spasm, we have developed the animal models of the spasm.
Animal models of coronary artery spasm
Based on the clinical observations that coronary artery spasm frequently occurs at the angiographically atherosclerotic lesions of the coronary artery, we first examined whether experimental atherosclerotic coronary lesion, induced by a combination of balloon endothelium removal and high-cholesterol feeding, exhibits hyperresponsiveness to vasoconstrictor agents in pigs in vivo. 57, 58 Although the degree of the atherosclerotic lesion was too mild to detect angiographically, intracoronary administration of serotonin or histamine repeatedly induced coronary artery spasm at the atherosclerotic lesion ( Figure 5A ), and there was a close topological correlation between the spastic site and atherosclerotic lesion ( Figure 5B ).
57,58
These results provided the first experimental evidence for the close relationship between coronary artery spasm and coronary atherosclerosis, 57,58 which was subsequently confirmed in patients who underwent coronary balloon angioplasty 59 and those with vasospastic angina. 60 In this first porcine model, however, endothelial dysfunction is inevitable because of endothelial regeneration after endothelium removal 61, 62 and it was practically difficult to separate the role of endothelial dysfunction and VSMC hypercontraction in this first model. 63 Based on the pathological reports that the spastic human coronary artery had extensive adventitial inflammation and perivascular nerve lesions, 64 -66 we then examined whether experimental adventitial inflammation could cause vasospastic activity of the coronary artery without endothelium removal in pigs in vivo. Two weeks after the adventitial application of interleukin-1b (IL-1b), coronary angiography showed the development of mild stenotic lesion, where intracoronary administration of serotonin, histamine or platelet activating factor (PAF) repeatedly caused coronary spasm but not at the control site ( Figure 5C ). 67 -71 Histological examination showed adventitial accumulation of inflammatory cells, mild neointimal formation, and a marked reduction in vascular cross-sectional area (negative remodelling) ( Figure 5D ) 67 -71 and VSMC phenotypes were altered towards dedifferentiation at the spastic site. 70 In this second porcine model, endothelial vasodilator functions were fairly preserved as expected. 72 These vascular effects were not specific for IL-1b, because the same adventitial treatment with other inflammatory cytokines (e.g. IL-1a and TNF-a) also induced the similar histological and functional alterations of the porcine coronary artery. 70 These results provided the first experimental evidence for the role of adventitial inflammation in the pathogenesis of coronary artery spasm, indicating that among the components of atherosclerosis, inflammatory changes play a major role in the pathogenesis of the spasm.
Endothelial dysfunction vs. vascular smooth muscle cell hypercontraction Accumulating evidence has indicated that VSMC hypercontraction plays a major role in the pathogenesis of coronary spasm, whereas the role of endothelial dysfunction may be minimal (Table 1) . First, coronary spasm occurs at a given site of the atherosclerotic coronary artery, whereas endothelial dysfunction is rather generalized throughout the epicardial coronary arteries and systemic arteries throughout the body. 9, 73 Second, vasodilating responses to bradykinin 74 or substance P, 75 -77 acutely abolish coronary spasm by VSMC relaxation but have no acute beneficial effect on endothelial dysfunction, indicating that coronary spasm is a phenomenon of VSMC hypercontraction. 86 Finally, as discussed later, there are lines of direct evidence that coronary spasm is caused by VSMC hypercontraction mediated by Rho-kinase activation ( Table 1) . Indeed, it was shown that contractility of Translational research on coronary vasomotion coronary VSMC is augmented at the spastic coronary segment in a patient with variant angina 87 and as mentioned later in detail, in the porcine models of coronary artery spasm. 88, 89 Furthermore, it has been demonstrated in the second porcine model with IL-1b that VSMC hypercontraction plays a primary role while endothelial vasodilator function is fairly well preserved both in vivo and in vitro.
67,72
Mechanism of vascular smooth muscle cells hypercontraction When agonists (e.g. serotonin and histamine) bind to their receptors, phospholipase C is activated, leading to the formation of inositol 1,4,5-triphosphate (IP 3 ) and diacylglycerol by the hydrolysis of phosphatidyl-inositol 4,5-bis-phosphate ( Figure 6A ). GTPase Rho and its target, Rho-kinase ( Figure 6A ).
93,94
Vascular smooth muscle cells hypercontraction and coronary artery spasm Coronary artery spasm is caused primarily by VSMC hypercontraction. However, the vasocontracting response to increasing Ca 2+ concentrations is unaltered in VSMC from spastic coronary artery in our first porcine model. 88 Subsequently, it was also reported that vasocontracting response to increasing concentrations of Ca 2+ is unaltered in aortic VSMC from Watanabe hereditary hyperlipidaemic rabbits as compared with normal rabbits. 95 These results suggest that Ca 2+ sensitivity of contractile proteins per se is unaltered at the spastic site and that the key mechanism for coronary spasm is present somewhere between receptors and contractile proteins in the signal transduction pathway for VSMC contraction ( Figure 6A) . Furthermore, in the second porcine model with IL-1b, coronary hypercontraction is mediated primarily by the 5-HT 2A serotonergic receptor, whereas the expression or functions (receptor affinity and number) of the 5-HT 2A receptor are not significantly altered when compared with normal coronary arteries. 96 These results suggested that the key mechanism for the spasm is present somewhere below the receptors and above the contractile proteins in the signal transduction pathway for VSMC contraction ( Figure 6A ). In addition to the receptor-mediated stimulation by serotonin or histamine, direct activation of PKC by phorbol esters also causes coronary spasm while inhibition of PKC (by PKC inhibitors, such as staurosporine and sphingosine) suppresses it in both the first 97 and the second porcine models. 98 Coronary artery spasm induced by serotonin or histamine was also inhibited by the PKC inhibitors.
97,98
The inhibitory effects of the PKC inhibitors were specific because they did not inhibit the coronary contractions induced by prostaglandin F 2a (PGF 2a ). 97, 98 These results indicated that the PKC-mediated pathway is substantially involved in the pathogenesis of coronary spasm ( Figure 6A ). In our porcine models of coronary spasm, the spasm was also induced by Bay K 8644, a direct opener of L-type Ca channel, which was also inhibited by the PKC inhibitors ( Figure 6A) . 97, 98 These results suggested that Ca 2+ entry through L-type Ca channel into VSMC is the initial trigger for coronary spasm and that Ca 2+ entry might be augmented via PKC-dependent mechanism ( Figure 6A) . 97, 98 Indeed, it has been demonstrated that L-type Ca channel is functionally up-regulated at the spastic site in our first porcine model. 99 Enhanced myosin light-chain phosphorylations and coronary artery spasm Phosphorylation of MLC is one of the most important steps for VSMC contraction. 92 Figure 6A) . 92, 100 It was reported that MLC phosphorylation is augmented in canine vasospastic cerebral artery after experimental subarachnoid hemorrhage 101 and in hyperplastic rabbit carotid artery after balloon injury.
102
In our porcine model with IL-1b, MLC monophosphorylation was enhanced at the spastic coronary segment and MLC diphosphorylation, which was never observed in the normal coronary artery, was also induced during serotonin-induced coronary spasm. 89 There was a positive correlation between the serotonin-induced coronary vasocontractions and MLC mono-and diphosphorylations. 89 Fasudil, an inhibitor of protein kinases with 10 times more potent inhibitory effect against PKC (Ki Phenotype modulation of VSMC (from growth-arrested type to actively growing type) was noted in the neointimal regions of the atherosclerotic artery. 106 In cultured VSMC, MLC diphosphorylation is enhanced in actively growing cells compared with growth-arrested cells. 107 In the second porcine model, the phenotype of VSMC (myosin heavy chain isoforms) is altered towards dedifferentiation. 70 These results suggest that MLC diphosphorylation occurs only in the actively growing cells in the spastic coronary artery. The phenotype change of arterial VSMC may thus be one of the important mechanisms of coronary artery spasm. The generation of diphosphorylated MLC is caused in part by inhibition of MLC phosphatase in VSMC. 102 The treatment with calyculin A, a protein phosphatase inhibitor, potently induces MLC diphosphorylation in VSMC without an increase in intracellular Ca 2+ levels. 107 In permeabilized porcine aortic VSMC, the increase in intracellular Ca 2+ levels causes MLC monophosphorylation alone, whereas additional treatment with GTP-g S, which is thought to inactivate MLC phosphatase, causes both mono-and diphosphorylation of MLC. 108 These results suggest that inhibition of MLC phosphatase activity is essential for induction of MLC diphosphorylation in VSMC. The mechanism of the inhibition of MLC phosphatase, however, remains to be clarified. Several important reports have been published on this issue. A novel inhibitor of MLC phosphatase that is potentiated by PKC (C-kinase-activated phosphatase inhibitor, CPI-17) has been isolated from porcine aortic media. 109 Rho-kinase phosphorylates the 130-kDa subunit of MLC phosphatase and reduces its activity. 90 All these mechanisms may be involved in the inhibition of MLC phosphatase at the spastic coronary segment ( Figure 6A ).
Rho-kinase and vascular smooth muscle cell hypercontraction Studies in vitro demonstrated that a GTP-binding protein regulates the receptor-mediated sensitization of the MLC phosphorylation 110 and that small GTPase Rho is involved in the GTP-enhanced Ca 2+ sensitivity of VSMC contraction. 93, 108 Importantly, Rho regulates MLC phosphorylation through its target, Rho-kinase, and the myosinbinding subunit (MBS) of myosin phosphatase. 94, 111 Smooth muscle MLC phosphatase consists of 38-kDa catalytic subunit, the 130-kDa MBS, and the 20-kDa subunit. 112, 113 The MBS serves as a target subunit of MLC phosphatase to myosin and enhances the activity of the enzyme towards myosin. 112 Activated Rho interacts with Rho-kinase to activate it. The activated Rho-kinase subsequently phosphorylates the MBS, thereby inactivating myosin phosphatase. 94 Rho-kinase itself might also phosphorylate MLC at the same site that is phosphorylated by MLCK, and activate myosin ATPase in vitro.
111
Activated form of Rho-kinase enhances MLC phosphorylation 114 and induces VSMC contraction, 115 stress fibre formation and neurite retraction 116 ( Figure 6A ). Both pathways, inhibition of myosin phosphatase and direct phosphorylation of MLC, may be involved in the increase in MLC phosphorylations. 115 Hydroxyfasudil, an active metabolite of fasudil after oral absorption, preferentially inhibits Rho-kinase compared with MLCK or PKC (at least 100 times more potent at IC50 levels). 105 Hydroxyfasudil causes dose-dependent inhibition of the serotonin-induced coronary spasm in the porcine model with IL-1b both in vivo and in vitro through suppression of serotonin-induced increases in MLC mono-and diphosphorylations. 105 Thus, the hydroxyfasudilsensitive Rho-kinase-mediated pathway plays an important role in the enhanced MLC phosphorylations in the spastic coronary artery ( Figure 6A ). In order to further elucidate the molecular mechanism of coronary spasm in our porcine model, experiments were performed to examine whether or not Rho-kinase is up-regulated at the spastic site and if so, how it induces VSMC hypercontraction. 117 RT-PCR analysis demonstrated that the expression of Rho-kinase mRNA and, to a lesser extent, that of RhoA mRNA were significantly up-regulated in the spastic than in the control segment. 117 Western blot analysis showed that during the serotonin-induced contractions, the extent of MBS phosphorylation was significantly greater in the spastic than in the control segment. Furthermore, another Rho-kinase inhibitor, Y-27632, 118 also inhibited not only serotonin-induced hypercontractions in vivo and in vitro but also the increase in MBS phosphorylations. 117 Importantly, there was a highly significant positive correlation between the extent of MBS phosphorylations and that of contractions in the spastic but not in the control segments. 117 These results indicate that Rho-kinase is up-regulated at the spastic site and plays a key role in inducing VSMC hypercontraction by inhibiting MLC phosphatase through MBS phosphorylation in our porcine model ( Figure 6A ).
117,119
Indeed, subsequent clinical studies showed that intracoronary fasudil is effective in almost all patients with epicardial coronary spasm ( Figure 6B ). 120 Importantly, intracoronary fasudil is also effective in relieving intractable coronary spasm resistant to nitrates and Ca channel blockers ( Figure 6C ). 121 Moreover, fasudil is effective to suppress microvascular coronary spasm in approximately two-thirds of patients with microvascular angina ( Figure 6D) . 122 These results indicate the usefulness of Rho-kinase inhibitors for the treatment of coronary vasospastic disorders. 91, 123, 124 Rho-kinase and cardiovascular diseases Accumulating evidence has indicated that Rho-kinase plays important roles in the pathogenesis of a wide range of cardiovascular diseases in general and coronary vasomotion abnormalities in particular ( Figure 7A) . 91, 123, 124 Indeed, the Rho/Rho-kinase pathway not only mediates VSMC hypercontraction thorough inhibition of MLC phosphatase as mentioned above but also promotes atherosclerotic process through enhancing cell responses towards the disorder ( Figure 7A) . 91, 123, 124 One of the recent topics on the Rho-kinase pathway is that the secretion of cyclophilin A (CyPA), which is a novel mediator of oxidative stress, is mediated by Rho-kinase ( Figure 7A) . 125, 126 We have recently identified that small GTP-binding protein dissociation stimulator (SmgGDS) plays a central role of the pleiotropic effects of statins independent of the Rho-kinase pathway ( Figure 7A ). 127 Furthermore, in a series of studies, we have demonstrated that the Rho-kinase pathway plays a crucial role in the pathogenesis of coronary hyperconstricting responses induced by drug-eluting stents (DESs) in pigs 128 and humans 129 and that longterm treatment with a long-acting nifedipine suppresses DES-induced coronary vasomotor abnormalities through indirect inhibition of Rhokinase pathway. 130 We have recently demonstrated that Rho-kinase activity in circulating leucocytes is a useful biomarker for coronary artery spasm, not only for the diagnosis of the disorder ( Figure 7B ) but also for the assessment of disease activity ( Figure 7C ) and efficacy of medical treatment ( Figure 7D ) 131 and that there is a circadian change of the activity with a peak noted in the early morning associated with chest symptoms. 132 Rho-kinase activity in circulating leucocytes of patients is also elevated in pulmonary hypertension, 133 chronic heart failure, 134 and cardiovascular diseases in general 135 although no correlation is noted with the level of high-sensitivity C-reactive protein. 134 Thus, the Rho-kinase activity may represent not only the extent of vasospastic disorder but also a new aspect of systemic inflammation. Taken together, the role of the Rho-kinase pathway in the pathogenesis of cardiovascular diseases has been emerging and the possible indications of Rho-kinase inhibitors have been expanding in cardiovascular medicine (Figure 8) . 91, 123, 124 Japanese coronary spasm association In order to develop evidence-based medicine on coronary artery spasm, we established the Japanese Coronary Spasm Association (JCSA) in 2006, in which 72 leading institutes in Japan participated (see Supplementary material online, Figure S1 ). We first performed the retrospective registry study of Japanese VSA patients, demonstrating that those who had survived out-of-hospital cardiac arrest are at high risk, 136 that the spasm provocation tests have an acceptable level of safety, 137 that there are gender differences in the characteristics and outcomes of VSA patients, 138 that the novel JCSA risk score may provide the comprehensive risk assessment and prognostic stratification for VSA patients, 139 and that combination therapy with long-acting nitrates and CCBs may be associated with reduced long-term survival. 86 We are now conducting the prospective international registry study of vasospastic angina in six countries, which should elucidate the unknown aspects of the disorder (Supplementary material online, Figure  S2 ). It is possible that the prevalence of coronary artery spasm in Western population is not so low as previously considered compared with Japanese population.
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Figure 8 Translational research on coronary vasomotion
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